Knowledge, acceptance, uptake barriers and missed opportunities of human papillomavirus vaccine among female adolescents in Benin City, Nigeria: A mixed method study
International Journal of Gynecology & Obstetrics · 2026
DOI: 10.1002/ijgo.70388 ↗Kurz gefasst
Mixed-Methods-Studie in der Zeitschrift International Journal of Gynecology & Obstetrics, 2026. Verfasst von Ese-Ose Obehi-Oye Imarengiaye und 4 weiteren Autor:innen. Beteiligte Einrichtung: Edo Specialist Hospital, Benin City, Edo State, Nigeria. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Vaccination, Health Knowledge, Attitudes, Practice, Patient Acceptance of Health Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Introduction
The human papillomavirus (HPV) vaccine has shown efficacy against cervical cancer and HPV‐related malignancies. The vaccine was recently introduced in Nigeria as a routine immunization, free for young girls aged 9 to 14 years. This study aimed to determine the knowledge, acceptance, uptake barriers and missed opportunities of HPV immunization among adolescents in Benin City, Nigeria.
Method
A descriptive cross‐sectional study using mixed methods for data collection was carried out in four secondary schools in Benin City, Nigeria, over a 3‐month period, following ethical approval. Quantitative data were analyzed using SPSS 25.0, and qualitative data were analyzed using themes. P ‐values were set at less than 0.05.
Results
There were 801 students with a mean age group of 14.3 ± 1.85. Only 56.5% had heard of the HPV vaccine; 15.5% had good knowledge of HPV, 23.4% received the vaccine, while 25.8% were willing to receive the vaccine when available. The reasons for refusal were fear of side effects (56.3%), fear of needles (18.2%), and lack of adequate information (11.3%). The missed opportunity was 71.9%. Fathers with primary level education and an odds ratio of 0.181 (95% confidence interval: 0.034–0.947, P = 0.043) and pupils of schools located in rural settings with an odds ratio of 0.369 (95% confidence interval: 0.205–0.665, P < 0.001) were less likely to accept the HPV vaccine. The teachers agreed that HPV vaccination was a good idea, while the parents shared divergent views.
Conclusion
In this study, the knowledge and acceptance of HPV vaccine were found to be low, and there was a significant proportion of missed opportunities. An improved public awareness campaign is advocated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Edo Specialist Hospital, Benin City, Edo State, Nigeria.
- Department of Obstetrics and Gynaecology, University of Benin Teaching Hospital, Benin City, Edo State, Nigeria.
- Department of Public Health and Community Medicine, University of Benin Teaching Hospital, Benin City, Edo State, Nigeria.
ORCID-Profile: Ese-Ose Obehi-Oye Imarengiaye, Reuben Obioma Iweka, Chidinma Joy Anya
Zitieren
APA
Imarengiaye, E. O., Iweka, R. O., Anya, C. J., Nwaogwugwu, J. C., & Ofili, A. N. (2026). Knowledge, acceptance, uptake barriers and missed opportunities of human papillomavirus vaccine among female adolescents in Benin City, Nigeria: A mixed method study. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.70388
Vancouver
Imarengiaye EO, Iweka RO, Anya CJ, Nwaogwugwu JC, Ofili AN. Knowledge, acceptance, uptake barriers and missed opportunities of human papillomavirus vaccine among female adolescents in Benin City, Nigeria: A mixed method study. International Journal of Gynecology & Obstetrics. 2026. doi:10.1002/ijgo.70388
BibTeX
@article{Imarengiaye2026,
author = {Imarengiaye, Ese-Ose Obehi-Oye and Iweka, Reuben Obioma and Anya, Chidinma Joy and Nwaogwugwu, Joy Chinyere and Ofili, Antoinette Ngozi},
title = {Knowledge, acceptance, uptake barriers and missed opportunities of human papillomavirus vaccine among female adolescents in Benin City, Nigeria: A mixed method study},
journal = {International Journal of Gynecology & Obstetrics},
year = {2026},
doi = {10.1002/ijgo.70388}
}
EUVIMED